JP Morgan analyst Tessa Romero maintains Upstream Bio (NASDAQ:UPB) with a Neutral and raises the

Truist Securities analyst Danielle Brill maintains Upstream Bio (NASDAQ:UPB) with a Buy and lower

Upstream Bio (NASDAQ:UPB) reported quarterly losses of $(0.73) per share which beat the analyst cons

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasa

JP Morgan analyst Tessa Romero downgrades Upstream Bio (NASDAQ:UPB) from Overweight to Neutral an

Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory dis

HC Wainwright & Co. analyst Matthew Caufield initiates coverage on Upstream Bio (NASDAQ:UPB)

– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom

Mizuho analyst Joseph Catanzaro maintains Upstream Bio (NASDAQ:UPB) with a Outperform and lowers

Upstream Bio (NASDAQ:UPB) reported quarterly losses of $(0.75) per share which beat the analyst cons

The presentations feature new data from the Phase 2 VIBRANT trial evaluating verekitug, the only kno

Sanofi reports positive Phase 2 data for lunsekimig in asthma and nasal polyps, while atopic dermati

Evercore ISI Group analyst Cory Kasimov downgrades Upstream Bio (NASDAQ:UPB) from Outperform to I

U.S. stock futures down, Zenas Biopharma shares fall 9.5% in pre-market trading due to pricing of pu

Upstream Bio outlines Phase 3 plans for verekitug as asthma and CRSwNP data support dosing strategy;

– Company to pursue Phase 3 development strategy designed to deliver best-in-class efficacy with a h

Upstream Bio stock fell after mixed asthma drug data, but analysts say the selloff may be overdone d

Upstream Bio shares rise after Phase 2 data show its asthma drug cut attacks by up to 56% and improv

Verekitug provided statistically significant and clinically meaningful reductions in annualized asth

Mizuho analyst Joseph Catanzaro initiates coverage on Upstream Bio (NASDAQ:UPB) with a Outperform